BIOPHARMA.com
BIOPHARMA.org
.com domains for all the major gene therapy vectors, e.g., AAVvectors.com, lentiviralvectors.com
and over 100 others

Background:  'Biopharma(ceutical):'
1) Within the industry, science, etc. this term often still retains its original/classic biotechnology-grounded definition involving pharmaceuticals manufactured using biotechnology (living organisms), with 'biopharma(ceutical)' a subset of 'pharma(ceutical).'
2) In the past decade-plus with push from industry, "biopharma(ceutical)" has become (or soon enough will be) the preferred popular/common and industry's-own term for the global pharmaceutical industry and its products, particularly where desiring to project a positive image.  'Biopharma(ceutical)' has or is replacing 'pharma(ceutical)' in common and industry use, much as 'pharma(ceutical)' replaced use of 'drug' in the 1970s/80s.  [This broad industry Pharma(ceutical) → Biopharma(ceutical) renaming/rebranding trend is nothing new.  See a related Nature Biotechnology article, "(Re)Defining Biopharmaceutical," I authored ~17 years ago].  Or the term sometimes in context is used to refer to innovative/R&D-intensive (bio)pharmaceuticals and companies and/or the largest (Big Pharma) companies.  Despite the wide variations in definitions of "biopharma," few users ever cite the definition/scope they are using, leading to inconsistent and erroneous reporting about the industry.

'Biopharma' is a >$1 trillion revenue/year industry using the now predominant broad definition; and is now a >$500 billion/year subset of the pharmaceutical/drug industry using the classic definition.  The traditional 'Pharma(ceutical)' industry can be seen as genuinely having become the 'Biopharma(ceutical)' industry as biopharmaceutical (using the classic biotech-grounded defintion) R&D and product revenue and profits now top that of chemically-derived/synthetic pharmaceuticals.  With this, 'biopharma(ceutical)' has essentially replaced 'pharma(ceutical)' in common usage; clearly assisted by the global pharmaceutical industry, long publicly claiming to be 'biopharmaceutical.'  .

The world's leading (bio)pharmaceutical companies and trade groups long ago switched to using 'biopharmaceutical' to refer to and (re)brand themselves, their products and the industry.  PhRMA has been prominently citing its members as and using the tagline/subtitle "America's Biopharmaceutical Companies" now since late 2005 (20 years!); and "The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the biopharmaceutical industry operating in Europe."  Along with the switch to using 'biopharma(ceutical),' 'pharma(ceutical)' and 'drug' are increasingly evoking negative perceptions and becoming legacy, deprecated, simply no longer used.  For example, try to find any use by PhRMA at its Website or in its "flagship publication" and related "Industry Toolkits." 

As with "pharma," the word "biopharma(ceutical)" has universal recognition and is used both as an adjective (e.g., biopharma R&D, products, companies, etc.) and a noun (e.g., biopharmaceuticals; "Biopharma" referring to the industry).  Google retrieved 26.3 million entries for the exact word "biopharma" (in quotes) and 101.0 million for "biopharma" (truncated) (on Jan. 18, 2024; these nos. vary daily).  Use of "Biopharma(s)" to refer to companies is a new trend e.g., Google retrieved >30,000 entries in Sept. 2023 and 48,700 on Jan. 18, 2024.  There are >600 publicly traded companies in the U.S. with "biopharma" in their name (SEC); and a total of >2,000 "biopharma" companies in the U.S. and ~4,000 worldwide (D&B).  There are >2,650 "biopharma" (no truncation) company entries in Cruchbase and >800 in LinkedIn.  Over 4,150 domain names contain, >1,100 names start with and >2,500 end with "biopharma." 

BIOPHARMA Internet Dominance:  Top-level domain ownership will provide your organization with exclusive and unbeatable "BIOPHARMA" Internet presence and branding opportunities!  How much is it worth to your organization to be recognized as a (or the) leading 'Biopharma' industry organization and/or be the top-level/first-used industry information source?  For example: 
a) Brand your Web site, company, trade group, products, technologies, services, information resources, etc. as "BIOPHARMA."  Be known as the 'biopharma" leader.
b) Be known as the leading source for information and promote your image and views about the biopharmaceutical industry; its products, technologies, public affairs, etc.; and/or otherwise
c) Greatly improve the impact and cost-effectiveness of your public relations, marketing, advertising, lobbying, etc.  Such a prominent domain is its own perpetual advertising campaign.  The utility, impact, benefits and cost-effectiveness of a 'BIOPHARMA' domain will surely be much higher than the usual episodic and transitory advertising, marketing, public relations, lobbying, efforts.  For a 1-time purchase at a fair price (open for bids now), this IP can remain yours forever.

There will be no better top-level industry-defining IP available.  The only potential competition, "pharma.com," is tainted, was used by opioid epidemic-associated Purdue Pharma and is being sold as part of its bankruptcy proceedings (but who wants to be seen as "pharma" vs. "biopharma?")

An Established Brand:  All trends and indicators point to increasing value of this IP.  "Biopharma(ceutical)" is already a unversally-recognized brand worldwide, with much invested in this by the industry (easily $100s of milliions).  Adoption of "biopharma(ceutical)" has been largely driven by 2 decades of industry self-promotion redefining and (re)branding itself as "biopharmaceutical."  This includes PhRMA annually spending a good portion of its multi-$100s million annual PR/advertising/lobbying efforts supporting this, such as the multi-year "GoBoldly" campaign.  Increasing common use and continuing worldwide 'biopharma(ceutical)'rebranding efforts by the industry will assure increasing value of this 'BIOPHARMA' IP for years to come! 

Besides conveying a positive image associated with high-tech research, life-saving products, innovation, being 'bio(tech)', etc., unlike 'drug' and 'pharma(ceutical),' 'BIOPHARMA' is simply the best short term for the (bio)pharmaceutical industry and products.  Alternatives, e.g., "biopharm," "biologics" and "biotech medicines," lack traction, have resisted catching on.  Self-promotion as "biopharma(ceutical)" by an increasing number of companies and trade associations worldwide provides this IP with $millions worth of related promotion annually.  The industry's good will, track record of innovation and successful responses to the Covid-19 pandemic continue to dramatically increase the value of 'biopharma' IP. 

'BIOPPHARMA" domains include U.S. trademark rights. We/BII formerly held a registered U.S. trademark for "BIOPHARMA" covering use for all digital formats, databases, etc., but this was cancelled due to Mr. Rader not noticing it needed renewal, with his wife dying that same month. With no one similarly using "BIOPHARMA" as a trademark, a domain purchaser hould have a clear path to registering it again.

Value:  To perhaps(???) put the current commercial value of this IP in some context, the 'closest' (industry top-end-type) published domain sales (in current $) include "drugs.com" which sold for >$1.2 million in 1999; "pharmacy.com" for $2.9 million in 2008 and; Rx.com for $1 million in 2019.  BIOPHARMA.com surely has comparable or more and broader utility and value than such legacy 'drug' and 'pharmaceutical' transactional (all used for online prescription sales) domains.  Good "brandable" (blank slate) single word .com domains now commonly sell for this much, often more.  "BIOPHARMA" is a truly exemplary, established, single word, industry-defining, world-wide recognized brand with the highest value and good will among all industries. 

Biopharma.com has received a "fair market" appraisal of $1,000,000 (for domain investor/reseller, not the end-user market) from AccurateAppraisals.com (M. Mann, #1 owner of domains, >300,000]. 

As intangible assets and corporate investments, the domains are solid and reliable.  Can you even imagine any loss of value or downsides to owning this IP?  Most likely you are already envisioning considerable benefits use of this IP could provide your organization.  Ownership, even without use, is also an excellent option, whether as a high return investment or for strategic denial of use (e.g., Abbvie purchased "biosimilars.com" from me ~10 years ago and has never used it).  Prudent use will add further to your domain's value.